Open Access

Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B

  • Authors:
    • Yuki Tsuji
    • Tadashi Namisaki
    • Kosuke Kaji
    • Hiroaki Takaya
    • Keisuke Nakanishi
    • Shinya Sato
    • Soichiro Saikawa
    • Yasuhiko Sawada
    • Kou Kitagawa
    • Naotaka Shimozato
    • Hideto Kawaratani
    • Kei Moriya
    • Ryuichi Noguchi
    • Takemi Akahane
    • Akira Mitoro
    • Hitoshi Yoshiji
  • View Affiliations

  • Published online on: May 27, 2020     https://doi.org/10.3892/etm.2020.8798
  • Pages: 985-995
  • Copyright: © Tsuji et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chronic hepatitis B (CHB) virus continues to be a leading cause of morbidity and mortality worldwide. The diagnosis of liver fibrosis has a key role in selecting patients with CHB for antiviral treatment. However, serum biomarkers demonstrate limited diagnostic utility. The present study aimed to compare the performances of fibrosis biomarkers for diagnosing significant liver fibrosis that indicates the need for antiviral therapy in patients with CHB and to identify the most appropriate biomarker for these patients. The current study included 96 antiviral‑naïve patients with CHB who underwent liver biopsy. METAVIR scoring system was used to assess liver fibrosis and necroinflammation. The diagnostic performances were evaluated of the platelet (PLT) count; the levels of hyaluronan, serum 7S domain of type 4 collagen, procollagen type III N‑terminal peptide, tissue inhibitor of metalloproteinases 1, Mac‑2 binding protein glycosylation isomer (M2BPGi) and N‑terminal type III collagen propeptide (Pro‑C3); the fibrosis index based on four factors; the aspartate aminotransferase‑to‑platelet ratio index; and enhanced liver fibrosis score for identifying significant liver fibrosis [≥fibrosis stage 2 (F2)]. All fibrosis biomarkers, except the Pro‑C3 level, correlated with the fibrosis stage. M2BPGi was better than other biomarkers for diagnosing ≥F2, with the highest area under the curve of 0.902. M2BPGi demonstrated a higher diagnostic accuracy for significant fibrosis than mild/severe fibrosis or cirrhosis. However, no significant correlation was observed between the M2BPGi level and fibrosis stage in patients with CHB having significant liver necroinflammation defined as ≥ necroinflammatory activity 2. The M2BPGi level and PLT count were exclusively correlated with the fibrosis stage in 73 patients without significant liver necroinflammation. M2BPGi demonstrated the highest diagnostic performance for significant fibrosis in patients having significant liver fibrosis with no significant liver necroinflammation. In conclusion, the M2BPGi level can accurately diagnose significant liver fibrosis that indicates the need for antiviral therapy in patients with CHB.

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tsuji Y, Namisaki T, Kaji K, Takaya H, Nakanishi K, Sato S, Saikawa S, Sawada Y, Kitagawa K, Shimozato N, Shimozato N, et al: Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B. Exp Ther Med 20: 985-995, 2020
APA
Tsuji, Y., Namisaki, T., Kaji, K., Takaya, H., Nakanishi, K., Sato, S. ... Yoshiji, H. (2020). Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B. Experimental and Therapeutic Medicine, 20, 985-995. https://doi.org/10.3892/etm.2020.8798
MLA
Tsuji, Y., Namisaki, T., Kaji, K., Takaya, H., Nakanishi, K., Sato, S., Saikawa, S., Sawada, Y., Kitagawa, K., Shimozato, N., Kawaratani, H., Moriya, K., Noguchi, R., Akahane, T., Mitoro, A., Yoshiji, H."Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B". Experimental and Therapeutic Medicine 20.2 (2020): 985-995.
Chicago
Tsuji, Y., Namisaki, T., Kaji, K., Takaya, H., Nakanishi, K., Sato, S., Saikawa, S., Sawada, Y., Kitagawa, K., Shimozato, N., Kawaratani, H., Moriya, K., Noguchi, R., Akahane, T., Mitoro, A., Yoshiji, H."Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B". Experimental and Therapeutic Medicine 20, no. 2 (2020): 985-995. https://doi.org/10.3892/etm.2020.8798